Hikma Pharmaceuticals (LON:HIK) had its price target raised by JPMorgan Chase & Co. from GBX 1,050 ($13.72) to GBX 1,900 ($24.83) in a report published on Tuesday. JPMorgan Chase & Co. currently has a neutral rating on the stock.
Other equities analysts have also issued research reports about the stock. Peel Hunt reiterated an add rating on shares of Hikma Pharmaceuticals in a report on Tuesday, September 4th. Citigroup lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,675 ($21.89) to GBX 2,100 ($27.44) and gave the company a buy rating in a report on Monday, August 20th. Barclays upgraded shares of Hikma Pharmaceuticals to an equal weight rating and lifted their target price for the company from GBX 1,400 ($18.29) to GBX 1,800 ($23.52) in a report on Tuesday, November 6th. Finally, Numis Securities restated a hold rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 15th. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of GBX 1,672.43 ($21.85).
Shares of HIK opened at GBX 1,691.50 ($22.10) on Tuesday. Hikma Pharmaceuticals has a fifty-two week low of GBX 814.20 ($10.64) and a fifty-two week high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Story: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.